文献速递其他结缔组织病

系统性硬化症随机对照试验:下一代试验的患者选择与终点

Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials.
PubMed 文献 · Lancet Rheumatol · 2020-01-01

本文回顾近4年系统性硬化症(SSc)最具相关性的随机对照试验,讨论疾病异质性与多因素发病机制对试验设计的影响。作者指出,获批阳性3期试验多靶向组织损伤通路而非系统性免疫激活,提示当前试验设计可能存在选择偏倚,并提出下一代试验设计要点。

要点

  • SSc自然史异质性大,是临床管理与试验设计的主要难题。
  • 阳性的3期试验多针对组织损伤通路,而非系统性免疫激活。
  • 下一代SSc试验需基于发病机制与自然史进展优化患者选择与终点。

核心结论

  • SSc的疾病异质性与复杂多因素发病机制决定试验设计难度,阳性的3期试验多靶向组织损伤相关通路而非系统性免疫激活,提示当前试验设计可能存在选择偏倚。
  • 基于对发病机制与自然史认识进展,作者提出下一代SSc试验设计需重点考虑的关键要点。

研究设计与样本

  • 本文为Series论文,回顾并评述过去4年与SSc未来试验策略最相关的随机对照试验。

主要发现

  • 许多SSc试验靶向免疫激活通路,但阳性的3期试验靶向的是与组织损伤直接相关的通路而非系统性免疫激活。
  • 这些阳性结果促成该病首批获批药物,同时揭示当前试验设计方法可能存在选择偏倚。

临床怎么用

  • 下一代SSc试验设计应结合对发病机制与自然史的新认识,重视患者选择与终点设置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The heterogeneity in the natural history of systemic sclerosis is a major issue in both clinical management and trial design and is dictated by the complex and multifactorial pathogenesis of the disease. Systemic sclerosis is an autoimmune disease and therefore many trials for the disease have targeted immune activation pathways; however, the phase 3 trials that have been positive have targeted pathways directly linked to tissue damage rather than systemic immune activation. On one hand, these results represent enormous progress that has led to the first approved drugs for this extremely challenging condition. On the other hand, they have revealed a possible selection bias in our current approach to trial design. In this Series paper, we describe randomised controlled trials from the past 4 years we believe to be most relevant to future strategies in systemic sclerosis. Based on advances in our understanding of the pathogenesis and natural history of disease, we will also identify important points to consider in the design of the next generation of systemic sclerosis trials.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Del Galdo F, Hartley C, Allanore Y, et al. Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatol. 2020. PMID: 38263655. doi:10.1016/S2665-9913(20)30007-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。